Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia

NCT00036088 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 530

Last updated 2006-07-19

No results posted yet for this study

Summary

The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia

Conditions

Interventions

DRUG

Olanzapine

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2001-08-31
Completion
2002-07-31

Countries

  • United States
  • Argentina
  • Austria
  • Brazil
  • Germany
  • Ireland
  • Mexico
  • Peru
  • Puerto Rico
  • Spain
  • United Kingdom
  • Venezuela

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036088 on ClinicalTrials.gov